Cuprina Holdings Cayman Limited's

The company’s product portfolio includes bioactives with properties that enhance performance compared to conventional treatments, supported by clinical and health economic outcomes data. Its current offerings include maggot-based chronic wound care products designed to disinfect wounds and promote healing in patients unresponsive to standard treatments. Pipeline products under development include medical grade leeches for hirudotherapy and bullfrog sponge dressings intended to compete with other animal-derived collagen wound care dressings in Singapore. The bullfrog sponge dressings are planned for markets such as the United States, Singapore, Hong Kong, mainland China, Saudi Arabia, and ASEAN countries, subject to research, development, and regulatory approvals. The company is also researching additional bullfrog collagen-based products. Prior to development, it conducts comprehensive assessments of feasibility, clinical need, patient population, potential competitors, regulatory requirements, and associated risks for new medical devices.